BioCrine
  • Home
  • About Us
    • Company and People
    • Board of Directors
    • Management
    • Partners
  • Research Programs
    • Pipeline overview
    • Diabetes as a disease
    • Biocrine drug discovery strategy
    • Serum factor apoCIII
    • Somatostatin receptors
    • Insulin receptor isoforms
    • Calcium channels
    • Imidazolines
    • IP7
  • InSight Technology
    • What is it?
    • How does it work?
    • Where can it be used?
  • News
  • Contact
Home » Company news
Per-Olof Berggren has been elected to The National Academy of Medicine

Per-Olof Berggren has been elected to The National Academy of Medicine

Posted in: Company news|October 17, 2016

Per-Olof Berggren has been elected to The National Academy of Medicine The National Academy of Medicine announced today the election of 70 U.S. members and 9 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have …

Read more »
Professor Berggren’s distinctions 2012

Professor Berggren’s distinctions 2012

Posted in: Company news, Society|January 3, 2013

Professor Per-Olof Berggren has received 4 major distinctions during 2012:  Alex Hirsch from Karolinska Institutet, Wallenberg Scholars, The Novo Nordisk Foundation Advanced Grant and Kroc Lecture at Boston University Medical Center. Professor Berggren’s distinctions are for the following achievements: Axel Hirsch Prize from Karolinska Institutet. The prize is for scientific achievements, which are potentially of major significance to the treatment of …

Read more »
Biocrine featured in NyTeknik

Biocrine featured in NyTeknik

Posted in: Company news, Society|November 14, 2012

Biocrine’s CEO Professor PO Berggren was interviewed by NyTeknik, Swedish leading technology and IT newspaper. Treating diabetes with transplanted insulin-producing islets of Langerhans was the main subject of the discussion. Transplantation into the eye is a novel method developed by Prof Berggren’s research group. So far, the procedure has been thoroughly tested in mice leading …

Read more »
Biocrine’s home page launched

Biocrine’s home page launched

Posted in: Company news|February 21, 2012

www.biocrine.se is live Our company web site www.biocrine.com is now launched. We will be looking forward to your feedback on info@biocrine.se. With best regards, The Biocrine team

Read more »
Biocrine’s CEO featured at IVA’s annual meeting

Biocrine’s CEO featured at IVA’s annual meeting

Posted in: Company news, Society|February 21, 2012

        On the 28th of October 2011, Biocrine was featured as one of the prominent life science companies on the 92nd annual meeting of IVA. In an interview for IVA, Biocrine’s CEO Per-Olof Berggren talked about the main focus of the research; understanding of how a healthy insulin producing beta cell works, …

Read more »

Categories

Recent posts

  • Professor Berggren’s research publications
    Professor Berggren’s research publications February 1, 2019
  • Short anti-rejection therapy protects transplants in diabetic animals
    Short anti-rejection therapy protects transplants in diabetic animals February 1, 2019
  • Per-Olof Berggren invald i the American Academy of Arts and Sciences
    Per-Olof Berggren invald i the American Academy of Arts and Sciences October 4, 2018
  • New potential target for treatment of diabetes
    New potential target for treatment of diabetes July 29, 2018
  • Per-Olof Berggren elected member of the Korean Academy of Science and Technology
    Per-Olof Berggren elected member of the Korean Academy of Science and Technology June 13, 2018
  • The body’s “glucostat” identified
    The body’s “glucostat” identified March 9, 2018
  • Method developed that gives researchers better conditions for studying insulin-producing cells
    Method developed that gives researchers better conditions for studying insulin-producing cells September 3, 2017
  • Per-Olof Berggren has been elected to The National Academy of Medicine
    Per-Olof Berggren has been elected to The National Academy of Medicine October 17, 2016
  • The anterior chamber of the eye is a transplantation site that supports and enables visualisation of beta cell development in mice
    The anterior chamber of the eye is a transplantation site that supports and enables visualisation of beta cell development in mice April 13, 2016
  • Non-invasive cell type selective in vivo monitoring of insulin resistance dynamics
    Non-invasive cell type selective in vivo monitoring of insulin resistance dynamics February 22, 2016

Biocrine AB

Box 3073

169 03 Solna, Sweden

Contact Us

info at biocrine.se

www.biocrine.com

Copyright © 2012 Biocrine AB. All Rights Reserved